.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
Thermo Fisher Scientific recently announced a major microbiology business sale to private equity firm Astorg. This deal carries a value of approximately $1.08 billion. Consequently, the transaction includes cash and a $50 million seller note. This specific unit provides antimicrobial susceptibility testing and culture media products. These tools are essential for clinical, pharmaceutical, and food safety applications.
The unit belongs to the specialty diagnostics segment at Thermo Fisher. Furthermore, it generated $645 million in revenue during 2025. This divestiture allows the company to manage its portfolio more actively. Therefore, they can deploy capital to create higher shareholder value. However, the transaction will likely reduce adjusted earnings initially. Specifically, the company expects a $0.15 impact per share in the first full year after the close.
The company expects the sale to close in the second half of 2026. Consequently, medical professionals in India should monitor potential changes in product availability. Astorg is a well-known private equity firm with a history of scaling healthcare assets. Thus, this transition might lead to new investments in the microbiology sector. Additionally, Thermo Fisher will provide more financial details during their next earnings call.
Q1: What does the Thermo Fisher microbiology business produce?
The unit supplies antimicrobial susceptibility testing and culture media products used in clinical, pharmaceutical, and food safety settings.
Q2: When will the transaction between Thermo Fisher and Astorg be finalized?
The companies expect the deal to close during the second half of 2026, pending regulatory approvals.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice or replace professional judgment. Refer to the latest local and national guidelines for clinical practice.
References
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
Thermo Fisher Scientific is selling its microbiology business to Astorg for $1.08 billion to focus on specialty diagnostics and shareholder value....
4 months ago
A new study reveals that lipid-related metabolic dysregulation, marked by elevated TG/HDL-C ratio and glymphatic changes, independently impacts survival in idiopathic normal pressure hydrocephalus.
Today
A premature neonate developed upper limb compartment syndrome after uterine rupture extruded the arm through a scar defect. Conservative management with continuous monitoring yielded complete functional recovery and normal limb growth at 10-year follow-up, highlighting non-operative safety in selected cases.
Today
A meta-analysis of 13 propensity score-matched studies shows ViV-TAVR delivers lower early mortality and reduced bleeding compared to redo-SAVR for degenerated bioprosthetic aortic valves, though long-term hemodynamics warrant careful anatomical and patient-centered evaluation.
Today
Endoscopic posterior cervical fusion combines minimally invasive decompression, joint preparation, and rigid screw-rod fixation for atlantoaxial pathologies. Early clinical findings demonstrate solid bony union, excellent symptom relief, and minimal soft-tissue morbidity without significant vascular compromise.
Yesterday
The All-India Food Processors' Association has approached the Supreme Court to oppose FSSAI's proposed per-100g benchmark for front-of-pack warning labels, advocating instead for a per-serving threshold. We explore the regulatory showdown, nutritional evidence, and implications for clinical lifestyle counseling.
Today
